A5007131126- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Cancer Treatment and Pharmacology
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Advanced Breast Cancer Therapies
- Cancer-related Molecular Pathways
- Gastric Cancer Management and Outcomes
- Ubiquitin and proteasome pathways
- Eicosanoids and Hypertension Pharmacology
- Peroxisome Proliferator-Activated Receptors
- Cancer, Hypoxia, and Metabolism
- DNA Repair Mechanisms
- Adenosine and Purinergic Signaling
- Medical Imaging Techniques and Applications
- RNA modifications and cancer
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Angiogenesis and VEGF in Cancer
- Gallbladder and Bile Duct Disorders
- Pediatric Hepatobiliary Diseases and Treatments
- Zebrafish Biomedical Research Applications
The University of Texas MD Anderson Cancer Center
2019-2024
Baylor College of Medicine
2016
Endocrine Society
2015
Texas Southern University
2008-2013
Abstract Zanidatamab is a bispecific human epidermal growth factor receptor 2 (HER2)-targeted antibody that has demonstrated antitumor activity in broad range of HER2-amplified/expressing solid tumors. We determined the zanidatamab patient-derived xenograft (PDX) models developed from pretreatment or postprogression biopsies on first-in-human phase I study (NCT02892123). Of 36 tumors implanted, 19 PDX were established (52.7% take rate) 17 patients. Established PDXs represented...
<p>Figure S1, Figure S2, FIgure S3, S4, S5, S6, S7, S8</p>
<div>AbstractPurpose:<p>Biliary tract cancers, which are rare and aggressive malignancies, rich in clinically actionable molecular alterations. A major challenge the field is paucity of relevant biliary cancer models that recapitulate diverse profiles these tumors. The purpose this study was to curate a collection patient-derived xenograft (PDX) reflect spectrum genomic alterations present cancers create resource for modeling precision oncology.</p>Experimental...
<div>AbstractPurpose:<p>Datopotamab deruxtecan (Dato-DXd) is a humanized anti–trophoblast cell-surface antigen-2 (TROP2) IgG1 mAb linked to potent topoisomerase I inhibitor payload (DXd). Dato-DXd has already shown antitumor activity in breast cancer; however, the determinants of response, including importance TROP2 expression, remain unclear. We tested panel cancer patient-derived xenografts (BCX) varying expression.</p>Experimental Design:<p>The and...
<p>Supplementary Figure 1. Comparison of TROP2 membrane expression between patient tumors and matched derived xenografts. Supplementary 2. Representative images IHC in the breast cancer xenografts shown Images represent one three cores a TMA assessed, with at 20X. 3. Genomic alterations genes associated DNA damage repair. 4 BRCAness BCX models 5. Violin plot signature responders non-responders. 6. Homologous repair 7. Antitumor activity Datopotamab deruxtecan (Dato-DXd) PARP inhibitor...
Abstract Purpose: Cyclin E (CCNE1) has been proposed as a biomarker of sensitivity to adavosertib, Wee1 kinase inhibitor, and mechanism resistance HER2-targeted therapy. Experimental Design: Copy number genomic sequencing data from The Cancer Genome Atlas MD Anderson Center databases were analyzed assess ERBB2 CCNE1 expression. Molecular characteristics tumors patient-derived xenografts (PDX) assessed by next-generation sequencing, whole-exome fluorescent in situ hybridization, IHC. In...
Muscle proteolysis in CKD is stimulated when the ubiquitin-proteasome system activated. Serum glucocorticoid–regulated kinase 1 (SGK-1) involved skeletal muscle homeostasis, but role of this protein CKD–induced wasting unknown. We found that, compared with muscles from healthy controls, patients and mice express low levels SGK-1. In mice, SGK-1-knockout (SGK-1-KO) induced loss that correlated increased expression ubiquitin E3 ligases known to facilitate degradation by ubiquitin-proteasome,...
Abstract TROP2 antibody drug conjugates (ADCs) are under active development. We seek to determine whether we can enhance activity of ADCs by increasing expression. In metaplastic breast cancers (MpBC), there is limited expression TROP2, and downregulating transcription factor ZEB1 upregulates E-cad thus sensitizing ADC sacituzumab govitecan (SG). Demethylating agent decitabine decreases DNA methyltransferase promoter methylation subsequently increases Decitabine treatment as well...
The Wnt receptor ROR1 has generated increased interest as a cancer therapeutic target. Research on several approaches involving this is ongoing; however, tissue expression remains understudied. We performed an immunohistochemistry analysis of protein in large cohort multiple tumor and histologic types. analyzed 12 anonymized multi-tumor microarrays (TMAs), including mesothelioma, esophageal upper gastrointestinal carcinomas, uterine endometrioid carcinoma, among other Additionally, we...
Abstract Most tumors with activating MAPK (mitogen-activated protein kinase) pathway alterations respond poorly to MEK inhibitors alone. Here, we evaluated combination therapy inhibitor selumetinib and MDM2 KRT-232 in TP53 wild-type altered colon thyroid cancer models. In vitro, showed synergy between on cell proliferation colony formation assays. Immunoblotting confirmed p53 upregulation inhibition. The was tested vivo seven patient-derived xenograft (PDX) models (five colorectal carcinoma...
// Nicci Owusu-Brackett 1 , 2 Kurt W. Evans 3 Argun Akcakanat Erkan Yuca Coya Tapia 4 Yasmeen Qamar Rizvi Ecaterina Ileana Dumbrava Filip Janku and Funda Meric-Bernstam 5 6 Department of Surgical Oncology, The University Texas MD Anderson Cancer Center, Houston, TX 77030, USA Current address: General Surgery, Health San Antonio, 78229, Investigational Therapeutics, Translational Molecular Pathology, Breast Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Therapy, Correspondence...
Datopotamab deruxtecan (Dato-DXd) is a humanized anti-trophoblast cell-surface antigen-2 (TROP2) IgG1 mAb linked to potent topoisomerase I inhibitor payload (DXd). Dato-DXd has already shown antitumor activity in breast cancer; however, the determinants of response, including importance TROP2 expression, remain unclear. We tested panel cancer patient-derived xenografts (BCX) varying expression. The and isotype-control-DXd (IgG-DXd) was assessed against 11 BCXs 10 representing tumors...
<p>Supplementary Table 1: Genomic and biomarker data of zanidatamab co-clinical trial xenograft models.</p><p>Genomic models. Patient biomarkers/NGS has four categories: (+), (-), N/A, Gain</p><p>Supplementary 2: Event-free survival relative treatment-to-control ratios for PDXs.</p><p>Event-free PDXs.</p><p>Supplementary 3. PDXs compared to patient response.</p><p>Event-free response.</p><p>Supplementary 4....
<p>Supplementary Figure 1: HER2 status of patients and corresponding PDX models. expression was assessed by IHC ERBB2 amplification FISH NGS. FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; NGS, next-generation sequencing. Alterations represents genomic alterations available CLIA testing on archival patient samples (matching hosts). results were not for matching PDX.003.025, PDX.003.263, PDX.003.230.</p><p>Supplementary 2:...
<p>Supplementary Table 1: Genomic and biomarker data of zanidatamab co-clinical trial xenograft models.</p><p>Genomic models. Patient biomarkers/NGS has four categories: (+), (-), N/A, Gain</p><p>Supplementary 2: Event-free survival relative treatment-to-control ratios for PDXs.</p><p>Event-free PDXs.</p><p>Supplementary 3. PDXs compared to patient response.</p><p>Event-free response.</p><p>Supplementary 4....
<div>Abstract<p>Zanidatamab is a bispecific human epidermal growth factor receptor 2 (HER2)-targeted antibody that has demonstrated antitumor activity in broad range of HER2-amplified/expressing solid tumors. We determined the zanidatamab patient-derived xenograft (PDX) models developed from pretreatment or postprogression biopsies on first-in-human phase I study (NCT02892123). Of 36 tumors implanted, 19 PDX were established (52.7% take rate) 17 patients. Established PDXs...
<p>Supplementary Figure 1: HER2 status of patients and corresponding PDX models. expression was assessed by IHC ERBB2 amplification FISH NGS. FISH, fluorescence in situ hybridization; HER2, human epidermal growth factor receptor 2; NGS, next-generation sequencing. Alterations represents genomic alterations available CLIA testing on archival patient samples (matching hosts). results were not for matching PDX.003.025, PDX.003.263, PDX.003.230.</p><p>Supplementary 2:...
<div>Abstract<p>Zanidatamab is a bispecific human epidermal growth factor receptor 2 (HER2)-targeted antibody that has demonstrated antitumor activity in broad range of HER2-amplified/expressing solid tumors. We determined the zanidatamab patient-derived xenograft (PDX) models developed from pretreatment or postprogression biopsies on first-in-human phase I study (NCT02892123). Of 36 tumors implanted, 19 PDX were established (52.7% take rate) 17 patients. Established PDXs...